Abstract
COVID-19 spreads abnormally compared to its counterparts in the same family "beta-coronaviruses". Today, we count more than 130 million affected humans affected by the COVID-19. Therefore, the study of means of prevention and treatment is an urgent need. Interestingly, the novel virus (SARS-CoV-2) has some similarities with SARS-CoV and MERS-CoV. It is known that heterologous immunity is well recognized within species of the same family. The use of previously recognized effective antibodies for SARS and MERS virus may prevent the COVID-19 pandemic. The objective of this study is to compare between SARS-CoV, MERS-CoV, and SARS-CoV-2 genomic and proteomic identity/similarity and their cross-immunity as well as their immunological features in the context of COVID-19 diseases prevention and treatment methods.